Form 4: United Therapeutics COO Exercises and Sells Shares Under 10b5-1 Plan

United Therapeutics' President and COO, Michael Benkowitz, executed stock option exercises and subsequent sales of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on December 30, 2024.
• The transactions were executed under a Rule 10b5-1 trading plan established on August 7, 2024.
• A total of 10,000 stock options were exercised at a price of $111 per share.
• The subsequent sales of common stock were executed at various prices, ranging from approximately $354.88 to $358.18 per share.
• The shares were held in trusts, with some trusts having family members as beneficiaries and others where Mr. Benkowitz and his spouse are co-trustees.
• The transactions resulted in a net decrease in the number of shares held directly by Mr. Benkowitz, but an increase in shares held indirectly through trusts.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction under a pre-arranged plan, which is neither particularly positive nor negative. The sale of shares could be seen as slightly negative, but the pre-planned nature mitigates this concern.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.
• The exercise of options at $111 and subsequent sale at higher prices indicates a profitable transaction for the reporting person.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react negatively to the sale of shares by a key executive, even if it is part of a pre-planned trading plan.
• There is a risk of misinterpretation of the transactions by investors, potentially leading to volatility in the stock price.

Industry Context

This type of transaction is common for executives of publicly traded companies, especially those with stock-based compensation. The use of a 10b5-1 plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, such as those in the biotechnology and pharmaceutical sectors, including companies like Amgen, Gilead Sciences, and Biogen.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The reported transaction is consistent with standard practices for executives managing their personal finances while adhering to securities regulations.

Stakeholder Impact

• Shareholders may have a neutral to slightly negative reaction to the sale of shares by a key executive, although the pre-planned nature of the transaction should mitigate concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates

Keywords

stock options, insider trading, Rule 10b5-1, share sale, beneficial ownership, United Therapeutics, UTHR, Michael Benkowitz